These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38269492)

  • 1. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
    Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
    Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data.
    Li B; Zhang J; Huang A; Chen Y; Wei Q
    Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
    Li D; Wang H; Qin C; Du D; Wang Y; Du Q; Liu S
    Clin Pharmacol Ther; 2024 Mar; 115(3):535-544. PubMed ID: 38069538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
    Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
    Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.
    Liu P; He M; Xu X; He Y; Yao W; Liu B
    Seizure; 2023 Aug; 110():203-211. PubMed ID: 37423166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
    Hu JL; Wu JY; Xu S; Qian SY; Jiang C; Zheng GQ
    J Headache Pain; 2024 Oct; 25(1):169. PubMed ID: 39375581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.